ftx-6058
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 26, 2020 (NCT04586985)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Extracellular calcium-sensing receptorANTAGONIST
CASR antagonist
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ncccc1-c1cc2c(n3cnnc13)NCc1c(F)ccc3c1[C@@H](CO3)CO2- Mol. weight
- 403.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6067682 ↗
- ChEMBLCHEMBL5204429 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05169580 | Phase 1 | Dec 13, 2021 | Fulcrum Therapeutics |
| NCT04586985 | Phase 1 | Oct 26, 2020 | Fulcrum Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fulcrum Therapeutics | For profit | 2 | 2 | 1 | 2020 |
1 organizations
Page 1 / 1